Literature DB >> 10735951

Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome.

J Dunphy1, M Oliver, A L Rands, C R Lovell, N J McHugh.   

Abstract

We report 14 patients with minocycline-induced lupus-like syndrome (four men, 10 women; mean age 27.8 years) who developed a lupus-like illness after chronic use of minocycline for acne (1-10 years, median 3.8). Clinical features resolved completely on drug withdrawal (mean follow-up 11 months) and reappeared in two patients who were rechallenged. Sera from all 14 patients contained antineutrophil cytoplasmic antibodies (ANCA) giving a perinuclear pattern on indirect immunofluorescence on ethanol-fixed human neutrophils (p-ANCA), whereas 14 control asymptomatic individuals taking minocycline for acne were ANCA-negative. Eleven of the 14 patients had elevated antimyeloperoxidase antibodies and 10 had antielastase antibodies on enzyme-linked immunosorbent assay, which diminished on extended follow-up, as did other serological abnormalities. Major histocompatibility complex class II typing demonstrated that all of the 13 patients tested were either HLA-DR4 (nine of 13) or HLA-DR2 (four of 13) positive, and all had an HLA-DQB1 allele encoding for tyrosine at position 30 of the first domain. Our findings suggest a model whereby the presence of p-ANCA may be a marker for the development of lupus-like symptoms in genetically susceptible individuals taking minocycline for acne.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10735951     DOI: 10.1046/j.1365-2133.2000.03357.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

Review 1.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

Review 2.  Reactive metabolites and adverse drug reactions: clinical considerations.

Authors:  Sandra R Knowles; Lori E Shapiro; Neil H Shear
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

Review 3.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 4.  A Spotlight on Drug-Induced Vasculitis.

Authors:  Kinanah Yaseen; Alana Nevares; Hiromichi Tamaki
Journal:  Curr Rheumatol Rep       Date:  2022-09-21       Impact factor: 4.686

Review 5.  ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review.

Authors:  Petar Lenert; Michael Icardi; Laila Dahmoush
Journal:  Clin Rheumatol       Date:  2013-04-21       Impact factor: 2.980

6.  Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial.

Authors:  Xin Shelley Wang; Qiuling Shi; Tito Mendoza; Steven Lin; Joe Y Chang; Raza H Bokhari; Hui-Kai Lin; Araceli Garcia-Gonzalez; Mona Kamal; Charles S Cleeland; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-10-15       Impact factor: 7.038

7.  An update on the management of acne vulgaris.

Authors:  Jonette Keri; Michael Shiman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-06-17

Review 8.  The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity.

Authors:  Volker M Lauschke; Magnus Ingelman-Sundberg
Journal:  Int J Mol Sci       Date:  2016-10-12       Impact factor: 5.923

9.  Associations between Antibiotics for Non-tuberculous Mycobacterial Infection and Incident Sjögren's Syndrome: A Nationwide, Population-based Case-control Study.

Authors:  Wen-Cheng Chao; Ching-Heng Lin; Yi-Ming Chen; Chiann-Yi Hsu; Jun-Peng Chen; Hsin-Hua Chen
Journal:  Sci Rep       Date:  2018-10-30       Impact factor: 4.379

Review 10.  A Review of Systemic Minocycline Side Effects and Topical Minocycline as a Safer Alternative for Treating Acne and Rosacea.

Authors:  Ana M Martins; Joana M Marto; Jodi L Johnson; Emmy M Graber
Journal:  Antibiotics (Basel)       Date:  2021-06-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.